Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
An assessment of PET and CMR radiomic features for the detection of cardiac sarcoidosis.
Front Nucl Med
January 2024
Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom.
Article Synopsis
- The study investigates the effectiveness of [F]FDG PET and LGE-CMR imaging methods for distinguishing cardiac sarcoidosis (CS) from myocardial inflammation resulting from COVID-19.
- It involved analyzing image data from 35 post-COVID-19 patients and 40 CS patients, focusing on extracting and testing radiomic features to improve diagnostic accuracy for these conditions.
- The results indicated that the combined signature of features from [F]FDG PET performed exceptionally well with an AUC of 0.98 and accuracy of 0.91, while LGE-CMR achieved an accuracy of 0.75 and AUC of 0.87, highlighting the potential of machine learning classifiers in enhancing diagnostic outcomes.
Challenges for augmenting intelligence in cardiac imaging.
Lancet Digit Health
October 2024
Division of Cardiovascular Disease and Hypertension, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
Article Synopsis
- AI is being used in heart imaging to help doctors, but it hasn't yet proven to lower healthcare costs or improve patient outcomes.
- There are challenges like not enough data, privacy issues, and the need for better collaboration between hospitals that make it hard for AI to be fully effective.
- Instead of replacing doctors, AI should be seen as a helpful tool to support their work, improving communication and decision-making in patient care.
Tc-HFAPi SPECT imaging predicts left ventricular remodeling after acute myocardial infarction.
J Nucl Cardiol
August 2024
Department of Cardiology, Cardiovascualr Imaging Center, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China. Electronic address:
Background: Despite improved treatments for acute myocardial infarction (AMI), myocardial fibrosis remains a key driver of adverse left ventricular (LV) remodeling and increased mortality. Fibroblast activation and proliferation significantly contribute to this process by enhancing cardiac fibrosis, which can lead to detrimental changes in LV structure. This study evaluates the effectiveness of Tc-labeled fibroblast activation protein inhibitor (Tc-HFAPi) SPECT imaging in predicting LV remodeling over 12 months in post-AMI patients.
View Article and Find Full Text PDFRetrofitting the Heart: Explaining the Enigmatic Septal Thickening in Hypertrophic Cardiomyopathy.
Circ Heart Fail
May 2024
Comprehensive Heart Failure Center, Department of Translational Science University Clinic Würzburg, Germany (J.M.F., A.X., A.B., C.M., V.S.).
Hypertrophic cardiomyopathy is the most common genetic cardiac disease and is characterized by left ventricular hypertrophy. Although this hypertrophy often associates with sarcomeric gene mutations, nongenetic factors also contribute to the disease, leading to diastolic dysfunction. Notably, this dysfunction manifests before hypertrophy and is linked to hypercontractility, as well as nonuniform contraction and relaxation (myofibril asynchrony) of the myocardium.
View Article and Find Full Text PDFUnderstanding the Utility of Endocardial Electrocardiographic Imaging in Epi-Endocardial Mapping of 3D Reentrant Circuits.
medRxiv
November 2024
College of Computing and Information Sciences, Rochester Institute of Technology, Rochester, NY, USA.
Background: Studies of VT mechanisms are largely based on a 2D portrait of reentrant circuits on one surface of the heart. This oversimplifies the 3D circuit that involves the depth of the myocardium. Simultaneous epicardial and endocardial (epi-endo) mapping was shown to facilitate a 3D delineation of VT circuits, which is however difficult via invasive mapping.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!